Featured Research

from universities, journals, and other organizations

MGH Researchers Unravel Structure Of A Key Protein Involved In Tumor Angiogenesis And Metastasis

Date:
March 13, 2002
Source:
Massachusetts General Hospital
Summary:
Cancer cells need a blood supply to grow. A key receptor protein called the alpha V beta 3 integrin directs formation of new blood vessels by binding to other proteins, such as angiostatin and endostatin, produced by tumor cells. Scientists at Massachusetts General Hospital (MGH) have now deciphered the detailed structure of this protein as it interacts with its ligand (the protein that binds to a receptor). The work comes on the heels of findings published last year by the MGH investigators on the structure of the same protein in its resting unbound state.

Cancer cells need a blood supply to grow. A key receptor protein called the alpha V beta 3 integrin directs formation of new blood vessels by binding to other proteins, such as angiostatin and endostatin, produced by tumor cells. Scientists at Massachusetts General Hospital (MGH) have now deciphered the detailed structure of this protein as it interacts with its ligand (the protein that binds to a receptor). The work comes on the heels of findings published last year by the MGH investigators on the structure of the same protein in its resting unbound state. The new data, which will appear in a future issue of Science, are being published March 7 on the Science Express website (http://www.sciencexpress.org).

Related Articles


"By knowing the intricate molecular interactions between this receptor and its ligand, we are now in a better position to devise inhibitors that block this interaction and therefore prevent or forestall tumor angiogenesis and progression," says M. Amin Arnaout, MD, senior author, director of the MGH Structural Biology Program and chief of the MGH Renal Unit. Arnaout says this integrin receptor is also used by breast cancer cells to escape into the bloodstream and metastasize. "With this new information, we might be able to intercept that process as well," says Arnaout.

The MGH scientists also found that alpha V beta 3 integrin changes its shape when bound to its ligand, allowing it to send chemical signals instructing tumor cells to grow and spread. "Defining this shape-shift at the atomic level may also be harnessed therapeutically by designing more selective drugs with fewer side effects," says Arnaout.

There are 23 additional integrin receptors in humans, all with similar structural motifs. Some of these play important roles in other diseases -- such as osteoporosis, stroke, heart attack, diabetes, nephritis and rheumatoid arthritis -- and all bind to their protein ligands in a similar manner. "Catching an integrin in the act of binding to its ligand will offer new means of developing drugs to other debilitating diseases besides cancer," says Arnaout.

The other members of the research team include Jian-Ping Xiong, PhD, and Thilo Stehle, PhD, of the MGH -- who along with Arnaout are members of the MGH Structural Biology Program -- Matthias Frech, PhD, and Simon Goodman, PhD, of Merck KGaA in Germany, and Rongguang Zhang, PhD, and Andrzej Joachimiak, PhD, of the Argonne National Laboratory in Illinois. The study was supported by research grants from the National Institutes of Health and the U.S. Department of Energy.

The Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $300 million and major research centers in AIDS, the neurosciences, cardiovascular research, cancer, cutaneous biology, transplantation biology and photomedicine. In 1994, the MGH joined with Brigham and Women's Hospital to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups and nonacute and home health services.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts General Hospital. "MGH Researchers Unravel Structure Of A Key Protein Involved In Tumor Angiogenesis And Metastasis." ScienceDaily. ScienceDaily, 13 March 2002. <www.sciencedaily.com/releases/2002/03/020311080220.htm>.
Massachusetts General Hospital. (2002, March 13). MGH Researchers Unravel Structure Of A Key Protein Involved In Tumor Angiogenesis And Metastasis. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2002/03/020311080220.htm
Massachusetts General Hospital. "MGH Researchers Unravel Structure Of A Key Protein Involved In Tumor Angiogenesis And Metastasis." ScienceDaily. www.sciencedaily.com/releases/2002/03/020311080220.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Liberia Releases Last Ebola Patient, But Threat Remains

Liberia Releases Last Ebola Patient, But Threat Remains

Newsy (Mar. 5, 2015) Liberia&apos;s last Ebola patient has been released, and the country hasn&apos;t recorded a new case in a week. However, fears of another outbreak still exist. Video provided by Newsy
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins